Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Investors stake $31.5mm in iPierian

Executive Summary

Stem cell therapeutics developer iPierian has received $31.5mm in a first round of financing from various backers. Kleiner Perkins Caufield & Byers and Highland Capital Partners together invested $20mm; MPM Capital, $10mm; and FinTech Capital Partners, $1.5mm. Representatives from each of the investors will take seats on the company's board. IPierian was recently formed through the merger of pluripotent stem cell companies iZumi Bio and Pierian to accelerate the development of new cardiovascular, metabolic, and neurology therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies